KCAS

What KCAS does

KCAS Bio is a global bioanalytical contract research organization (CRO) founded in 1979 and headquartered in the Kansas City metro (Olathe, Kansas), providing GLP/GCP-compliant preclinical and clinical testing services to pharmaceutical, biotechnology, and animal health drug development programs. The firm operates a horizontal bioanalytical portfolio spanning small-molecule analysis, large-molecule ligand binding assays (LBA), hybrid LC-MS/MS workflows, immunogenicity testing (ADA/NAb), pharmacokinetics and pharmacodynamics (PK/PD), biomarker quantification, spectral flow cytometry, molecular biology (qPCR/ddPCR), dose formulation analysis, and central lab sample kitting. Laboratory facilities are located in Olathe (Kansas City, ~70,000 sf), Philadelphia (Spring House Innovation Park, ~26,000 sf including 9,000 sf of BSL2+), Lyon, France (~10,000 sf in Bioparc), and Melbourne, Australia (via alliance partner Crux Biolabs), with a scientific staff that includes 65 or more PhD-qualified personnel.

The technology backbone covers ELISA, ELISpot, Meso Scale Discovery (MSD), Luminex bead multiplexing, LC-UV-Vis/Fluorescence, Lumipulse G, and the next-generation NULISA-Argo HT immunoassay platform, paired with LC-MS/MS, qPCR/ddPCR, and harmonized 5-laser Cytek Aurora spectral flow cytometers. KCAS Bio's primary technical differentiator is its claim to be the only globally harmonized spectral flow cytometry provider with standardized Cytek Aurora platforms across US, EU, and APAC sites, supporting multi-site assay transfer and global clinical trial consistency, including panels of up to 36 colors and 30+ preclinical flow cytometry assays developed since 2018. The firm reports an accumulated library of 6,200+ proprietary and non-proprietary assays and 315 drugs supported to regulatory approval, both serving as institutional-knowledge assets reinforced by a track record of 25 FDA audits completed without major findings.

Revenue is generated under professional services agreements negotiated per study or program, with multi-year master contracts for larger sponsors and a direct enterprise sales motion that emphasizes consultative scientific engagement, FDA audit history, and multi-site harmonization. The customer base divides into three demand pockets: large pharma and biotech sponsors running regulated preclinical and clinical bioanalysis (primary segment), advanced therapy developers (cell, gene, vaccine, immunotherapy) needing specialized assays for ADCs, AAV shedding studies, and immunophenotyping, and discovery-stage programs requiring flexible, fast-turnaround method development (reported as 5 days for method development and 10 business days for core validation). Commercial channels combine content-driven marketing (The Conversational Flow and The Weekly Bioanalysis podcasts, scientific webinars, published works, participation in conferences such as CYTO) with direct field sales engagement to pharmaceutical and biotech sponsors. KCAS Bio is privately held with no disclosed parent, private equity, or venture capital sponsor, operates through a US entity and a wholly-owned French subsidiary (KCAS Bio – SAS, formerly Active Biomarkers, acquired September 2022), and FlowMetric (acquired February 2022) continues to operate as a KCAS company focused on spectral flow cytometry services.

Name

KCAS

Legal name

KCAS Bio

Website

https://kcasbio.com

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

251–500 employees

Short description

KCAS Bio is a private global bioanalytical CRO providing GLP/GCP-compliant testing — small and large molecule analysis, immunogenicity, biomarkers, and spectral flow cytometry — to pharmaceutical and biotech drug development sponsors across labs in the US, France, and Australia.

Ownership category

akta.pro rank

Product category

Bioanalytical Contract Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Testing Laboratories and Services (54138)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), DMPK / ADME & Bioanalysis (HLAGAFAC), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

Keywords

• Bioanalytical testing services
• Contract research organization
• Pharmacokinetics analysis
• Biomarker assay development
• Immunogenicity testing

Headquarters

HQ city

Shawnee

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Contract Research Services: KCAS Bio generates revenue through contract research organization (CRO) service agreements with pharmaceutical and biotech companies. Services include method development, validation, and sample analysis for preclinical and clinical studies. Revenue is project-based with quotes typically negotiated per study or program.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

KCAS Bio is a bioanalytical contract research organization (CRO) that delivers GLP/GCP compliant testing services for pharmaceutical, biotech, animal health, and medical device sponsors across preclinical and clinical drug development. Its core offerings include small molecule bioanalysis, ligand binding assays (LBA) and hybrid LC-MS/MS for large molecules, immunogenicity (ADA/NAb) testing, pharmacokinetics/pharmacodynamics (PK/PD) analysis, biomarker testing, spectral flow cytometry, molecular biology (qPCR/ddPCR), dose formulation analysis, and central lab/clinical sample kitting. Services are executed across four laboratory sites in the US, Europe, and APAC under harmonized quality systems.

Product overview

KCAS Bio is a leading bioanalytical Contract Research Organization (CRO) providing comprehensive GLP/GCP compliant drug development services. The company offers a unified portfolio of bioanalytical services organized around core testing services (Small Molecule Bioanalysis, LBA for Large Molecules, Hybrid LC-MS/MS, Immunogenicity Testing, PK/PD, Biomarker Testing, Flow Cytometry, Molecular Biology, Dose Formulation, and Central Lab), supported by a technology platform backbone that includes ELISA, ELISpot, Meso Scale Discovery, Luminex, NULISA, LC-MS/MS, qPCR/ddPCR, and spectral flow cytometry. The company serves global biotech and pharmaceutical sponsors across therapeutic areas including oncology, immunology, cardiovascular, neurology, and rare diseases, with laboratory facilities in Kansas City, Philadelphia, Lyon (France), and Melbourne (Australia). KCAS has supported over 315 approved drugs on the market and developed over 6,200 proprietary and non-proprietary assays.

Differentiator

Problem solved

Functional benefit

Brands

• The Conversational Flow: Official podcast of KCAS Bio featuring conversations on bioanalytical topics and industry insights.
• The Weekly Bioanalysis

Products and services

• Small Molecule Bioanalysis Bioanalytical testing services for small molecule compounds using validated analytical methods, supporting preclinical and clinical drug development for pharmaceutical and biotech sponsors.
• LBA for Large Molecules
• Hybrid LC-MS/MS for Large Molecules
• Immunogenicity Testing
• Pharmacokinetics (PK)
• Pharmacodynamics (PD)
• Biomarker Testing
• Flow Cytometry
• Molecular Biology
• Dose Formulation
• Central Lab
• Global Spectral Flow Cytometry

Quantifiable outcome

• 315+ drugs supported have received regulatory approval
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Crux BiolabscoreStrategic or Co-development Partner · 12 September 2022Strategic alliance with Crux Biolabs in Melbourne, Australia for APAC spectral flow cytometry capabilities. KCAS Bio has invested in placing harmonized Cytek Aurora cytometers at Crux Biolabs, enabling global sponsors to access consistent flow cytometry services across US, EU, and APAC regions. Crux Biolabs is a full-service bioanalytical CRO supporting clients through preclinical to full clinical development, with advantageous Phase 1 clinical trial capabilities in Australia.
• Active BiomarkerscoreOthers · 12 September 2022Acquisition of Active Biomarkers, a French bioanalytical laboratory based in Lyon, France. The acquisition expanded KCAS Bio's European footprint and added capabilities in bioassays and cellular analysis. Active Biomarkers operated as a specialized bioanalytical lab prior to acquisition, strengthening KCAS Bio's regional support in Europe.
• Ascendia PharmaminorStrategic or Co-development PartnerCollaboration for nanoparticle production and analysis services addressing challenges faced by large pharma in nanoparticle formulation and characterization. Joint service offering combining Ascendia's nanoparticle expertise with KCAS Bio's bioanalytical capabilities.
• Cytek BiosciencescoreTechnology or IntegrationPartnership for implementation of next-generation Cytek Aurora spectral flow cytometry technology. FlowMetric (a KCAS company) partnered with Cytek to expand spectral flow capabilities, leveraging Cytek's instrumentation for harmonized multi-site flow cytometry operations.

Scale indicators9 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Altasciences:
• Frontage Laboratories: Frontage is a US-headquartered CRO focused on bioanalytical, CMC, and clinical lab services for pharma/biotech. Closest direct peer to KCAS — similar size, similar PK/PD/immunogenicity offering, similar small-and-large molecule orientation.
• Celerion: Celerion is a clinical-bioanalytical CRO specializing in early-stage clinical pharmacology, PK/PD, and bioanalytical services. Comparable to KCAS in scientific profile (PhD-heavy staff, regulated bioanalysis) and customer base (small-to-mid biotech and large pharma).

Broad incumbents

• Eurofins Scientific: Eurofins operates a global network of bioanalytical, PK/PD, and immunogenicity testing laboratories serving pharma and biotech sponsors. Directly comparable to KCAS as a bioanalytical CRO with global reach, but materially larger and offering a much broader testing portfolio.
• Labcorp Drug Development (Fortrea): Fortrea (spun out of Labcorp) is one of the largest global CROs with extensive bioanalytical, PK, biomarker, and immunogenicity service lines. Competes with KCAS for the same pharma/biotech sponsor projects but at meaningfully greater scale and with broader clinical-to-commercial capabilities.
• ICON plc: ICON is a top-5 global CRO with bioanalytical, bioassay, and central lab services. KCAS competes with ICON's bioanalytical lab for LBA, ligand-binding, and biomarker work; ICON also has prior overlap with KCAS talent (e.g., Dr. Rutherford's prior role leading ICON's Large Molecule Method Development team).
• Charles River Laboratories: Charles River provides bioanalytical, safety assessment, and CDMO services globally. Its bioanalytical and immunogenicity offerings overlap directly with KCAS's small/large molecule PK and ADA services, while also serving preclinical safety assessment.
• IQVIA: IQVIA operates Q2 Solutions, its central lab and bioanalytical business, providing LBA, LC-MS/MS, flow cytometry, and biomarker services globally. Direct competitor to KCAS in regulated bioanalysis with greater scale, integrated clinical, and data capabilities.
• WuXi AppTec: WuXi AppTec is a global CRO/CDMO with a large bioanalytical and DMPK group serving pharma and biotech. Comparable offering to KCAS across preclinical-to-clinical bioanalysis, but at vastly greater scale and with integrated discovery-to-manufacturing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCQ1LbAY37jI1CS_RWg2qI_Q
• LinkedInlinkedin.com/company/kcas-laboratories
• Xx.com/kcasbio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KCAS